After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Bristol-Myers Squibb recently announced positive topline results from its Phase 3 trials for Sotyktu, generating increased interest from rheumatologists despite some skepticism on efficacy metrics.

Learn more about whether Bristol-Myers Squibb Company or Corcept Therapeutics Incorporated is a better investment based on ...

Learn more about whether Bristol-Myers Squibb Company or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales. The National Institute for ...

BMS says it is combining AI and machine learning with its researchers’ expertise in drug targets and mechanisms of action, to ...

The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. | The drug discovery pact between Charles River Laboratories, Valo Health and ...

Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...